Last reviewed · How we verify
Evaluation Of Role Of Platelet Rich Plasma In Treatment Of Patients Suffering From Atrophic Rhinitis
An interventional hospital based study will be undertaken from February 2021 to February 2023 in order to determine the efficacy of platelet rich plasma as a new modality for treatment of patients suffering from atrophic rhinitis in Sohag university hospital.
Details
| Lead sponsor | Sohag University |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 40 |
| Start date | 2021-02-01 |
| Completion | 2023-02 |
Conditions
- Atrophic Rhinitis
Interventions
- nasal submucosal injection of platelet rich plasma
Primary outcomes
- Degree of change in histopathological pattern of nasal mucosa — 12 weeks after end of the procedure.
A nasal mucosal biopsy will be obtained in all cases. Five subheadings for histopathology; Each variable was assigned a score of 0, 1 or 2 where 0 representing normal nasal mucosal features, whereas 2 signifying extreme variation, 1. Status of epithelium: respiratory epithelium (pseudo stratified columnar ciliated epithelium, squamous metaplasia (partial/total ± keratinization); Denuded or not 2. Status of mucous cells (Normal glands / ↓ number and size / Absence) 3. Condition of blood vessels (Reduced vascularity or Dilated blood vessels / Periarteritis/ Endarteritis). 4. Tunica propria: Granulation tissue Presence of Chronic inflammatory cellular infiltrate Degree of Fibrosis Chronic inflammatory cellular infiltration with fibrosis Basement membrane (Normal / Ill-defined /Thickened) Seromucinus glands especially the serous component - Degree of change in patient satisfaction and quality of life — 12 weeks after end of the procedure.
Symptom score, Sinonasal Outcome Test 25 (SNOT 25) will be noted .